BeyondSpring - BYSI Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeyondSpring in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BYSI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BYSI, but not buy additional shares or sell existing shares.
View BYSI analyst ratings or view top-rated stocks.

6 equities research analysts have issued 1-year price targets for BeyondSpring's stock. Their BYSI share price forecasts range from $5.00 to $65.00. On average, they anticipate the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 1,810.8% from the stock's current price.
View analysts price targets for BYSI or view top-rated stocks among Wall Street analysts.

BeyondSpring's stock was trading at $4.53 at the beginning of 2022. Since then, BYSI stock has decreased by 65.3% and is now trading at $1.57.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, September 9th 2022.
View our BYSI earnings forecast.

BeyondSpring Inc. (NASDAQ:BYSI) released its quarterly earnings data on Wednesday, December, 29th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.11. The business earned $0.34 million during the quarter, compared to analyst estimates of $0.34 million. BeyondSpring had a negative trailing twelve-month return on equity of 144.52% and a negative net margin of 4,750.48%.

Based on aggregate information from My MarketBeat watchlists, some companies that other BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), Pfizer (PFE), Atara Biotherapeutics (ATRA), CorMedix (CRMD) and Dynavax Technologies (DVAX).

(BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO.

BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI."

BeyondSpring's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BNP Paribas Arbitrage SA (0.64%), Hennion & Walsh Asset Management Inc. (0.24%), Orion Portfolio Solutions LLC (0.08%) and Group One Trading L.P. (0.00%).

Shares of BYSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BYSI stock can currently be purchased for approximately $1.57.

BeyondSpring (NASDAQ:BYSI) has a market capitalization of $61.12 million and generates $1.35 million in revenue each year. The company earns $-64,180,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis.

BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The official website for the company is www.beyondspringpharma.com. The company can be reached via phone at (646) 305-6387, via email at general@beyondspringpharma.com, or via fax at 1-646-882-4228.